Robin Garner's questions to Processa Pharmaceuticals (PCSA) leadership • Q1 2022
Question
Robin Garner of Craig-Hallum inquired about the development strategy for PCS3117, the expected details of the mid-year data for next-generation capecitabine, and the effectiveness of recent efforts to boost enrollment for the PCS499 trial.
Answer
CEO Dr. David Young explained that for PCS3117, the company is developing roadmaps to identify the regulatory path with the highest probability of approval in the shortest time. For next-gen capecitabine, he stated the mid-year data will focus on increased potency and reduced side-effect-causing metabolites to define a go-forward dosage regimen. Regarding PCS499, Dr. Young confirmed that expanded patient outreach and a new pre-screening process are beginning to yield positive results after COVID-related delays.